Theravance Biopharma (FRA:0TB) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Theravance Biopharma's net issuance of preferred for the three months ended in Mar. 2024 was €0.00 Mil. The number is 0, which means that Theravance Biopharma has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Theravance Biopharma's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Theravance Biopharma Net Issuance of Preferred Stock Historical Data

The historical data trend for Theravance Biopharma's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Net Issuance of Preferred Stock Chart

Theravance Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Theravance Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Theravance Biopharma Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Theravance Biopharma Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (FRA:0TB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (FRA:0TB) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

TBPH:USA

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (FRA:0TB) Headlines

No Headlines